GHK-Cu

GHK-Cu is a three-amino-acid peptide bound to a copper ion, and it occurs naturally in human plasma, saliva and urine. Concentrations run highest in the young — around 200 ng/mL at twenty — and fall away substantially with age, which is what prompted researchers to ask whether restoring it might help maintain tissue. Loren Pickart first isolated it during the 1970s, then spent decades working out what it does; most of the foundational literature traces back to his lab, and that concentration of provenance is worth knowing when weighing it.

Framed honestly it is a cosmeceutical ingredient, with human evidence for topical use that is real and thin at the same time. It turns up in serums, creams and wound-care products, and small clinical trials have examined it for wrinkles, firmness and photoaged skin. Wound healing and hair follicle support have been explored in the lab and, to a lesser extent, in clinic [1] [2].

A separate and much weaker use case is compounded injectable GHK-Cu for systemic anti-aging effects, which extrapolates from cell and animal work. No large human randomized trial has examined the injectable form, and it holds no FDA approval as a drug. The distance between the topical evidence and the injectable claims is wide, and worth understanding before choosing either.

The main action is delivering copper. Copper is an essential cofactor for lysyl oxidase, which cross-links collagen; for superoxide dismutase, which scavenges free radicals; and for VEGF signaling in blood vessel growth. Chelating the ion in a stable but still bioavailable complex is how the peptide carries copper into tissue compartments that would otherwise be closed to it [6]. In human dermal fibroblasts, both the peptide and the complex stimulate TGF-beta secretion — an upstream driver of collagen and elastin synthesis — and adjust matrix metalloproteinases so that remodeling of the extracellular matrix proceeds in an orderly way [3].

There is also evidence the peptide backbone does something on its own, independent of the copper. A 2012 study found the copper-free form restoring stem-cell characteristics to the epidermis of aging skin, which implies direct signaling rather than pure delivery [4]. Bioinformatic analysis of large gene-expression datasets flagged it as something that shifts hundreds of genes bound up in repair and in damping inflammation — though nearly all of that work is computational and in vitro, and none of it has been confirmed in a controlled human trial [2].

Topical cosmetic use has the best human evidence, and it is worth being precise about how good that is. Small studies — mostly sponsored by cosmetic manufacturers or run in academic dermatology — report wrinkles shallower, skin denser and the surface smoother after eight to twelve weeks of daily use. Most enrolled under thirty people, most lacked placebo controls, and independent replication is largely absent. A 2016 preformulation study worked out the physicochemical properties needed to get the peptide through the stratum corneum, establishing that dermal delivery is achievable but depends heavily on concentration and formulation [5]. There is a genuine signal here; the trial quality does not support strong therapeutic claims on top of it.

Wound healing shows the same shape. Animal models consistently show wounds closing faster, more collagen laid down and less inflammation with topical application [1]. Human data are thin and come mostly from small observational reports rather than randomized trials. Hair follicles follow the pattern again: cell and animal work shows follicles enlarging and the growth phase lengthening, with no robust human regrowth trial to confirm it. Some dermatologists add copper peptide serums to hair-loss protocols, on an evidence base far thinner than the one behind minoxidil or finasteride.

For the injectable form, the summary is simply that human clinical evidence is absent. The argument for it runs by extrapolation — since the complex modulates collagen, inflammation and antioxidant pathways in cells and animals, delivering it systemically ought to amplify all three. Plausible, and unproven: no peer-reviewed randomized trial of injectable GHK-Cu in humans exists in the biomedical literature. Anyone considering it is operating outside the evidence base entirely, with no established safety profile for putting copper peptide into the bloodstream.

Topically it appears in serums and creams anywhere from 0.02% to 1%, with most commercial products landing between 0.1 and 0.5%. More is not automatically better and higher concentrations can irritate sensitive skin. Application is usually once or twice a day to clean skin, often beneath a moisturizer. Stability is a practical issue rather than a footnote: the complex degrades in high-pH or strongly oxidizing formulations, so how a product is made matters as much as what is in it.

For injection, some compounding-pharmacy providers offer 0.5 to 2 mg subcutaneously, two or three times a week. None of that comes from human pharmacokinetic study; it derives from preclinical work plus whatever prescribers have settled into. Nothing establishes an effective dose, nothing validates a duration, and no monitoring standard exists. Treat injectable use as experimental, because that is what it is.

Topical use is generally well tolerated at cosmeceutical concentrations. What gets reported is mild and passing: irritation, redness, or a temporary blue-green tint left by the copper complex. Copper at low doses is a nutrient the body requires, and a cream delivers very little of it through the skin, so systemic copper accumulation from a serum is not a realistic concern for most people.

Injection is a different risk profile altogether. Copper toxicity is well documented — nausea, liver injury, neurological effects — as a consequence of systemic overload. Whether compounded injectable doses can get near those thresholds has never been examined properly. That form holds no FDA approval, is not made under pharmaceutical quality controls, and has no characterized human safety profile. Anyone with Wilson's disease or another copper-metabolism disorder should avoid every form of it. And the usual compounded-injectable risks apply: infection at the site, and sterility you cannot verify.